What Is CagriSema? Trial Results, Status and Safety
CagriSema is an investigational once-weekly injection from Novo Nordisk that combines two molecules: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. It is being studied for weight management and type 2 diabetes. As of October 2026 it is not approved by the FDA, and the only legitimate access is through clinical trials. This guide explains how the combination works, what the major trials reported, which side effects appeared, and what “investigational” means for anyone who sees the name online.
TL;DR
- What it is: a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, given as a weekly subcutaneous injection in trials.
- What the data show: in the phase 3 REDEFINE 1 trial, mean body weight fell 20.4% at 68 weeks versus 3.0% with placebo.
- Main trade-off: gastrointestinal side effects were common, mostly during dose escalation.
- Status: Novo Nordisk submitted an FDA application on December 18, 2025. Review is ongoing, so CagriSema is not a marketed medicine.
CagriSema in plain terms
The name is a contraction of its two parts: Cagrilintide and Semaglutide. Semaglutide is already approved in other formulations and doses (it is the active ingredient in Wegovy). Cagrilintide is the newer element. It is not approved anywhere on its own, although Novo Nordisk plans a separate phase 3 program for it.
Both molecules are peptides, meaning short chains of amino acids. Each acts on a different appetite-related pathway. That is the entire premise of the combination: if one pathway produces a certain amount of weight reduction, a second, complementary pathway might add to it.
The product in the trials is a single fixed-dose injectable. It is not two separate syringes, and it is not something a person assembles from separate vials. That distinction matters later, when we get to products sold online under the same name.
How the two components work
Semaglutide: the GLP-1 side
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It slows gastric emptying, stimulates insulin release when glucose is high, and signals fullness to the brain. Semaglutide mimics this hormone but lasts far longer in the body, which is why weekly dosing is possible. The 2.4 mg dose has established weight-loss and cardiovascular benefits, according to the background of the published trial.
Cagrilintide: the amylin side
Amylin is a hormone made by the pancreas alongside insulin. It also promotes satiety and slows gastric emptying, but through different receptors than GLP-1. Cagrilintide is a long-acting amylin analogue. Early-phase studies showed promising results at 2.4 mg, which led to its pairing with semaglutide.
The researchers behind REDEFINE 1 describe the approach as combination therapy aimed at going beyond what GLP-1 monotherapy achieves, by engaging more than one satiety pathway. For readers who want a laboratory-side comparison of cagrilintide with another multi-target research compound, our article on retatrutide versus cagrilintide covers assay and COA considerations.
What the clinical trials showed
REDEFINE 1: weight management
The pivotal trial was published in the New England Journal of Medicine in 2025. Adults with overweight or obesity received weekly CagriSema (2.4 mg of each component) or placebo. According to the published results:
| Measure | CagriSema | Placebo |
|---|---|---|
| Estimated mean body weight change at 68 weeks | -20.4% | -3.0% |
| Mean absolute change | -26.6 kg | -3.6 kg |
A different analysis method, which estimates results if everyone had stayed on the assigned product, gave a larger figure. Novo Nordisk’s Canadian release reports 22.7% at 68 weeks. Both numbers come from the same trial. They answer slightly different questions, so be wary of any page that quotes one without saying which.
REIMAGINE 2: type 2 diabetes
In adults with type 2 diabetes inadequately controlled on metformin or SGLT2 inhibitors, REIMAGINE 2 reported a 1.91-point HbA1c reduction and 14.2% weight loss over 68 weeks, compared with 10.2% for semaglutide 2.4 mg alone. These are headline results announced by the sponsor, so the full peer-reviewed analysis is the better reference for fine detail.
A note on blood pressure and other outcomes
Secondary analyses have looked at blood pressure and other cardiometabolic markers, and the broader REDEFINE and REIMAGINE programs continue. Weight reduction in a trial is not the same as proven long-term outcomes, and that distinction is part of why regulators review these programs so carefully.
Is CagriSema better than semaglutide?
In the type 2 diabetes trial above, the combination outperformed semaglutide 2.4 mg alone on both HbA1c and weight. That is evidence of superiority within that trial population, at that dose, over that period. It does not mean it is the right choice for any individual. Higher efficacy came alongside a heavier gastrointestinal burden, and those two facts have to be read together by a prescriber, not by a headline.
Side effects and tolerability
The most frequent adverse events in REDEFINE 1 were gastrointestinal. According to the NEJM report:
- Gastrointestinal events occurred in 79.6% of CagriSema participants, against 39.9% with placebo.
- Nausea affected 55% versus 12.6% with placebo.
- Constipation affected 30.7% versus 11.6%.
- Roughly 5.9% of participants stopped treatment because of these events.
Most events occurred during dose escalation, the stepwise increase in dose that trials use to improve tolerability. That is one reason professional supervision of titration is a recurring theme in the clinical literature. It is also why a self-directed approach with an unverified product is a poor idea: dose, purity and sterility all matter more when the body is already adjusting to the drug.
Is CagriSema FDA approved? What “investigational” means
No. Novo Nordisk filed a New Drug Application with the FDA in December 2025, and review is ongoing. No official release date has been set by the company. Some consumer health coverage, such as Healthline’s overview, says a decision is expected by late 2026, but that is an expectation, not an announcement. Check the FDA and Novo Nordisk directly for current status.
“Investigational” has a specific meaning: access is limited to clinical trials and authorized research contexts. Healthline also warns that products sold as compounded CagriSema have not been reviewed by the FDA and may carry health risks, and it notes that cagrilintide cannot legally be used in compounding. Anyone claiming immediate availability of the finished product is operating outside the regulatory framework.
Why most peptides never reach approval
It helps to understand why a compound can be scientifically interesting and still unapproved. FDA approval requires large financial investment, multi-phase clinical trials and commercial backing. Compounds that occur naturally or are hard to patent often attract less funding, even when scientific interest continues. Approval status reflects economics and evidence together, which is why research peptides and approved drugs sit in different categories. Our explainer on why some peptides are sold for research use only walks through that distinction, and five FDA signals on why drug approval does not apply to RUO material covers the compliance side.
How long does it take to work, and when will it be available?
In REDEFINE 1, weight change was measured over 68 weeks, with dose escalation at the start. The trial does not support promising a timeline for any individual, and results varied between participants. As for availability, the realistic answer is that it depends on the FDA review outcome. Until then, CagriSema is a trial-only medicine.
What a clinician would want you to weigh
Trial numbers are strong, yet experts caution that public demand for the newest weight-loss compounds often outpaces understanding of long-term safety and individualized protocols. A physician who focuses on evidence-first care, such as the team behind clinician-led medical weight loss options, will usually start with history, labs and approved options before discussing anything investigational. If you are considering any weight-management approach, that conversation belongs with a licensed clinician who can examine you, not with a product page.
Our perspective at Peppy&Me
We see interest in CagriSema arrive from two very different directions: people who read a headline and want a product, and researchers who want to understand the pharmacology. We only serve the second group. Our catalog is for laboratory research use only, sold to authorized individuals and professionals aged 21 and over, and we do not offer, imply or support human use of anything we sell.
What we can contribute is rigor around the research materials themselves. Every lot is third-party tested for purity, mass accuracy, endotoxins, sterility and heavy metals, with lot and batch numbers that can be traced from manufacturer to warehouse. A COA that is lot-specific and independently produced is the baseline for credible bench work, whatever the compound. We also publish a peptide glossary and a dose calculator so researchers can handle reconstitution and measurement consistently.
Finally, we think CagriSema is a useful reminder of how the process should work: years of staged trials, published data, and a regulator’s review before a medicine reaches patients. Shortcuts are not a substitute for that.
— Peppy&Me
For laboratory researchers: where Peppy&Me fits
For researchers studying amylin-pathway biology, we list a cagrilintide 10 mg research peptide as a single-component research material, with lot-specific COA access. It is not CagriSema, it is not a finished or combined drug product, and it is not intended for human use. You can browse the wider research compounds catalog for peptides, amino acid derivatives and blended research materials. Orders placed before 2 PM ship the same day within the U.S.
How to evaluate any CagriSema claim you read
- Find the trial name. REDEFINE (weight management) and REIMAGINE (type 2 diabetes) are the main programs. Claims without a trial behind them are marketing.
- Check the analysis method. 20.4% and 22.7% describe the same trial under different assumptions.
- Read the side effects, not only the efficacy. A 79.6% gastrointestinal event rate is part of the result.
- Confirm the date. Regulatory status changes. Anything written before the FDA decision is a snapshot.
- Ask who is selling. Approved medicines come through licensed pharmacies on a prescription. Anything else should be treated with caution.
FAQ
Is CagriSema the same as semaglutide?
No. Semaglutide is one of its two components. CagriSema adds cagrilintide, an amylin analogue, in a single fixed-dose injection. The combination is investigational, while semaglutide is approved in other products.
What are the side effects of CagriSema?
In REDEFINE 1, gastrointestinal events such as nausea, vomiting, diarrhea and constipation were most common, reported by 79.6% of participants versus 39.9% on placebo. They clustered during dose escalation, and about 5.9% discontinued because of them. Discuss any symptoms with a licensed clinician.
When will CagriSema be available?
Novo Nordisk filed for FDA approval in December 2025 and the review is ongoing. No release date has been announced. Until the FDA acts, it is available only in clinical trials.
Can I buy CagriSema online?
No legitimate source sells it, because it is not approved. Products marketed as compounded CagriSema are not FDA-reviewed. Peppy&Me does not sell CagriSema or any product for human use; our materials are for laboratory research only.
Sources
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity, NEJM
- Novo Nordisk files for FDA approval of CagriSema
- Coadministered Cagrilintide and Semaglutide, PubMed record
- REDEFINE 1 Canadian press release, Novo Nordisk
- CagriSema REIMAGINE 2 results, Drug Topics
- CagriSema: FDA Status, Results, and Uses, Healthline